Terminated PHASE3 INTERVENTIONAL 1-arm NCT00381810

A Study to Evaluate the Safety of Rituximab Retreatment in Subjects With Systemic Lupus Erythematosus (VOYAGER)

An Open-label, Single-arm, Multicenter Phase II/III Extension Study to Evaluate the Safety of Rituximab Re-treatment in Subjects With Moderate to Severe Systemic Lupus Erythematosus Previously Enrolled in Protocol U2971g

Sponsor: Genentech, Inc.

Conditions Lupus Erythematosus, Systemic

Interventions Acetaminophen Diphenhydramine Methylprednisolone Rituximab

Updated 13 times since 2017 Last updated: Jul 5, 2017 Started: Jun 22, 2006 Primary completion: Jul 31, 2008 Completion: Feb 29, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

During a safety review of studies U2970g and U2971g, the Data Monitoring Committee recommended that enrollment in this extension trial be terminated.

Other terminated trials from Genentech, Inc.

More terminations from Genentech, Inc.

This PHASE3 trial investigates Lupus Erythematosus, Systemic and is currently terminated or withdrawn. Genentech, Inc. leads this study, which shows 13 recorded versions since 2006 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

13 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE3
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE3
Jan 2023 — Jul 2024 [monthly]

Terminated PHASE3
Dec 2022 — Jan 2023 [monthly]

Terminated PHASE3
Dec 2021 — Dec 2022 [monthly]

Terminated PHASE3

▶ Show 8 earlier versions

Jan 2021 — Dec 2021 [monthly]

Terminated PHASE3
Nov 2020 — Jan 2021 [monthly]

Terminated PHASE3
Jun 2018 — Nov 2020 [monthly]

Terminated PHASE3
May 2018 — Jun 2018 [monthly]

Terminated PHASE3
Sep 2017 — May 2018 [monthly]

Terminated PHASE3

Phase: PHASE2_PHASE3 → PHASE3
Aug 2017 — Sep 2017 [monthly]

Terminated PHASE2_PHASE3
Feb 2017 — Aug 2017 [monthly]

Terminated PHASE2_PHASE3
Jan 2017 — Feb 2017 [monthly]

Terminated PHASE2_PHASE3

First recorded

Jun 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Genentech, Inc.

Data source: Genentech, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Boise, United States , Charleston, United States , Chicago, United States , Coeur d'Alene, United States , Great Neck, United States , Kansas City, United States , Oklahoma City, United States , Paradise Valley, United States , San Leandro, United States , Seattle, United States and 1 more location